Navigation Links
Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
Date:12/8/2012

COLUMBUS, Ohio Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

The agent, ibrutinib (PCI-32765), is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) presented these findings today (12/8) at the 54th Annual Meeting of the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA.

The study found that response to therapy was high across cohorts, with 71 percent of previously untreated older patients experiencing a complete or partial response at either treatment dose (420mg and 840mg). The same response was observed in 67 percent of the relapsed patients and half (50%) of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

"These findings are truly exciting because they demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL that produces a high rate of durable remissions the remissions last months on end," Byrd says. "The drug is effective in part because patients are willing to stay on treatment since the side effects are very tolerable," he states.

Only non-severe side effects, including diarrhea, fatigue, chest infection, rash, nausea, joint pain and infrequent and transient low blood counts were observed. Investigators found no evidence of c
'/>"/>

Contact: Liz Bryan, Spectrum
lbryan@spectrumscience.com
443-506-1931
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EzCheckPrinting Updated with New Category Feature to Simplify Check Printing and Tax Reporting
2. Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine
3. Pure Cocoa Powder, the Key Ingredient in Dark Chocolate and Found in Diabetes Support Supplements has been Clinically Proven to Reduce Cardiovascular Risk
4. USC Norris cancer research ranks among top clinical advances for 2012
5. American Society of Clinical Oncology issues annual report on state of clinical cancer science
6. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
7. Study finds link between access to online health information and use of clinical services
8. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
9. Molecular portraits of tumours match patients with trials in everyday clinical practice
10. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
11. Spread of human melanoma cells in mice correlates with clinical outcomes in patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... 2015 , ... Lecrae is quickly developing into one of the biggest music ... New York Times to Billboard Magazine and Variety, among others. His transparency and ... why so many people are taking notice. , “We are very excited about this ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... be held October 28-31, 2015 at Disney’s Coronado Springs Resort in Lake Buena ... and networking. Each year, this premiere event for psychiatric-mental health nursing draws more ...
(Date:6/30/2015)... ... 2015 , ... Izenda is proud to acknowledge the hard ... an accredited American educational institution through its scholarship program. , In today's Age ... environment, political campaigns, and a variety of other worldwide trends. Modern day technology ...
(Date:6/30/2015)... ... June 30, 2015 , ... Americans report feeling more ... buzzer on Monday mornings, which puts stressed out people right over the edge. ... 22% suffering from sleep deprivation every night. Sleeping pills now lead the list of ...
(Date:6/30/2015)... ... June 30, 2015 , ... Scott Purdy, the spokesperson for ... Provider XO. Scott Purdy stated that the XO stands for eXtra Operability (XO) which ... the workflow processes of the Revenue Cycle. , Provider XO, based in Cleveland ...
Breaking Medicine News(10 mins):Health News:Hands of Hope to Present Grammy Award-Winner Lecrae in Concert this August 2Health News:Hands of Hope to Present Grammy Award-Winner Lecrae in Concert this August 3Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 2Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 3Health News:Izenda Offers Embedded BI and Analytics Scholarship 2Health News:Izenda Offers Embedded BI and Analytics Scholarship 3Health News:Wake UP Happy and Sleep Soundly with Famous Experts with My Wake UP Call® Motivational Alarm Clock® Messages and My Good Night Messages™ - Now Available at Audible! 2Health News:Wake UP Happy and Sleep Soundly with Famous Experts with My Wake UP Call® Motivational Alarm Clock® Messages and My Good Night Messages™ - Now Available at Audible! 3Health News:Dephinitive Systems Is Getting a New Name 2
... a third of American,adults take some type of multivitamin ... is better health, even though there is no firm ... one thing, but the presence of,harm is another: A ... concluded that there was an increased prostate cancer risk ...
... to Stethoscope, the distinguished public lecture series organized by ... (MUHC), is embarking on a second season. "Again this ... on a journey into a possible future, when current ... declared Dr. Arthur T. Porter, Director General of the ...
... The Russell,Investment Group has advised Protalix Biotherapeutics ... float weight adjustment effective after the close of,trading ... Russell 2000,Russell 2000 Growth, Russell 2500, Russell 2500 ... Growth, Russell Small Cap,Completeness and the Russell Small ...
... Sept. 28 Transcept,Pharmaceuticals, Inc., a specialty pharmaceutical ... drugs, today announced,that Glenn A. Oclassen, President and ... 2007 BIO Investor Forum at the Palace Hotel ... 3:00 PM Pacific Time. About Transcept Pharmaceuticals ...
... Doctors need to be more proactive in diagnosing the condition, ... in seven women suffers from depression before, during or after ... can be devastating to the mother, her baby and her ... of The American Journal of Psychiatry . , ...
... M. Williams Speak Out on Mental Health Crisis,Facing ... Experts in mental,health, Members of Congress and other ... Caucus Foundation,s 2007 Annual,Legislative Conference to shed light ... Needs." Rep. Julia Carson (D - IN) together,with ...
Cached Medicine News:Health News:Excessive Multivitamin Use May Raise Risk for Prostate Cancer, from Harvard Men's Health Watch 2Health News:Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment 2Health News:15% of Women Struggle With Pregnancy-Related Depression 2Health News:15% of Women Struggle With Pregnancy-Related Depression 3Health News:Black America Urged to Confront Its Secret Pain: Depression 2Health News:Black America Urged to Confront Its Secret Pain: Depression 3Health News:Black America Urged to Confront Its Secret Pain: Depression 4Health News:Black America Urged to Confront Its Secret Pain: Depression 5
(Date:6/30/2015)... June 30, 2015  Today, the National Mobility Equipment ... 2015 National Mobility Awareness Month Local Heroes Contest on ... online entries that received 1.3 million votes. The sponsors ... Toyota Mobility , and Valley Honda Dealers ... and Vantage Mobility International (VMI) and ...
(Date:6/30/2015)... Calif. , June 30, 2015  Avanir ... PRISM II study showing that treatment with NUEDEXTA ... reduction in symptoms of pseudobulbar affect (PBA) in ... PBA is a distressing condition characterized by sudden ... from certain neurologic diseases or brain injury. PRISM ...
(Date:6/30/2015)... Minn. , June 30, 2015  EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering  of 40,229,886 units. Each ... of a Series A warrant to purchase one share ... warrant to purchase one share of common stock, at ...
Breaking Medicine Technology:NMEDA Announces National Contest Winners 2NMEDA Announces National Contest Winners 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3